The multi-site prescription opioid addiction treatment study: 18-month outcomes

Journal of Substance Abuse Treatment

Volumn 48, Issue 1, 2015, Pages 62-69

  Potter, Jennifer Sharpe ^a,b,c   Dreifuss, Jessica A ^b,c   Marino, Elise N ^a   Provost, Scott E ^b   Dodd, Dorian R ^b   Rice, Lindsay S ^b   Fitzmaurice, Garrett M ^b,c,d   Griffin, Margaret L ^b,c   Weiss, Roger D ^b,c  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b MCLEAN HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Buprenorphine; Clinical trial; Follow up; Prescription opioids; Substance use disorder; Treatment

Indexed keywords

ALCOHOL; BUPRENORPHINE PLUS NALOXONE; CANNABIS; CENTRAL STIMULANT AGENT; COCAINE; DIAMORPHINE; OPIATE; OPIATE AGONIST; PRESCRIPTION DRUG; BUPRENORPHINE; NALOXONE; NARCOTIC ANTAGONIST;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG MISUSE; DRUG WITHDRAWAL; DSM-IV; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPIATE ADDICTION; OUTCOME ASSESSMENT; PAIN SEVERITY; PATIENT COUNSELING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBSTANCE USE; THERAPY; CLINICAL TRIAL; COUNSELING; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PRESCRIPTION DRUG MISUSE; PROCEDURES; TIME FACTOR;

ADULT; BUPRENORPHINE; COUNSELING; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NALOXONE; NARCOTIC ANTAGONISTS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; OUTCOME ASSESSMENT (HEALTH CARE); PRESCRIPTION DRUG MISUSE; TIME FACTORS;

EID: 84922819834     PISSN: 07405472     EISSN: 18736483     Source Type: Journal    
DOI: 10.1016/j.jsat.2014.07.009     Document Type: Article

References (36)

1. Beck A.T., Ward C.H., Mendelson M., Mock J., Erbaugh J. An inventory for measuring depression. Archives of General Psychiatry 1961, 4:561-571.
2. Blonigen D.M., Timko C., Finney J.W., Moos B.S., Moos R.H. Alcoholics Anonymous attendance, decreases in impulsivity and drinking and psychosocial outcomes over 16years: moderated-mediation from a developmental perspective. Addiction 2011, 106(12):2167-2177.
3. Bodkin J.A., Zornberg G.L., Lukas S.E., Cole J.O. Buprenorphine treatment of refractory depression. Journal of Clinical Psychopharmacology 1995, 15(1):49-57.
4. Carroll K.M., Rounsaville B.J., Nich C., Gordon L.T., Wirtz P.W., Gawin F. One-year follow-up of psychotherapy and pharmacotherapy for cocaine dependence. Delayed emergence of psychotherapy effects. Archives of General Psychiatry 1994, 51(12):989-997.
5. Cleeland C.S., Ryan K.M. Pain assessment: global use of the Brief Pain Inventory. Annals of the Academy of Medicine, Singapore 1994, 23(2):129-138.
6. Curran P.J., Muthen B.O., Harford T.C. The influence of changes in marital status on developmental trajectories of alcohol use in young adults. Journal of Studies on Alcohol 1998, 59(6):647-658.
7. Donovan D.M., Anton R.F., Miller W.R., Longabaugh R., Hosking J.D., Youngblood M. Combined pharmacotherapies and behavioral interventions for alcohol dependence (The COMBINE Study): Examination of posttreatment drinking outcomes. Journal of Studies on Alcohol and Drugs 2008, 69(1):5-13.
8. Dreifuss J.A., Griffin M.L., Frost K., Fitzmaurice G.M., Potter J.S., Fiellin D.A., et al. Patient characteristics associated with buprenorphine/naloxone treatment outcome for prescription opioid dependence: Results from a multisite study. Drug and Alcohol Dependence 2013, 131(1-2):112-118.
9. Emrich H.M., Vogt P., Herz A. Possible antidepressive effects of opioids: action of buprenorphine. Annals of the New York Academy of Sciences 1982, 398:108-112.
10. Festinger D.S., Marlowe D.B., Croft J.R., Dugosh K.L., Mastro N.K., Lee P.A., et al. Do research payments precipitate drug use or coerce participation?. Drug and Alcohol Dependence 2005, 78(3):275-281.
11. Fiellin D.A., Pantalon M.V., Schottenfeld R.S., Gordon L.T., O'Connor P.G. Manual for standard medical management of opioid dependence with buprenorphine 1999.
12. Gandhi D.H., Jaffe J.H., McNary S., Kavanagh G.J., Hayes M., Currens M. Short-term outcomes after brief ambulatory opioid detoxification with buprenorphine in young heroin users. Addiction 2003, 98(4):453-462.
13. Gowing L., Ali R., White J.M. Buprenorphine for the management of opioid withdrawal. Cochrane Database of Systematic Reviews 2009, (3):1-72. (CD002025).
14. Grella C.E., Joshi V., Hser Y.I. Followup of cocaine-dependent men and women with antisocial personality disorder. Journal of Substance Abuse Treatment 2003, 25(3):155-164.
15. Jones C.M. Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers - United States, 2002-2004 and 2008-2010. Drug and Alcohol Dependence 2013, 132(1-2):95-100.
16. Kramer J.R., Chan G., Kuperman S., Bucholz K.K., Edenberg H.J., Schuckit M.A., et al. A comparison of diagnoses obtained from in-person and telephone interviews, using the Semi-Structured Assessment for the Genetics of Alcoholism (SSAGA). Journal of Studies on Alcohol and Drugs 2009, 70(4):623-627.
17. Lundgren L.M., Amodeo M., Ferguson F., Davis K. Racial and ethnic differences in drug treatment entry of injection drug users in Massachusetts. Journal of Substance Abuse Treatment 2001, 21(3):145-153.
18. McLellan A.T., Kushner H., Metzger D., Peters R., Smith I., Grissom G., et al. The Fifth Edition of the Addiction Severity Index. Journal of Substance Abuse Treatment 1992, 9(3):199-213.
19. Midanik L.T., Greenfield T.K. Telephone versus in-person interviews for alcohol use: results of the 2000 National Alcohol Survey. Drug and Alcohol Dependence 2003, 72(3):209-214.
20. Moore B.A., Fiellin D.A., Barry D.T., Sullivan L.E., Chawarski M.C., O'Connor P.G., et al. Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients. Journal of General Internal Medicine 2007, 22(4):527-530.
21. National Archives and Records Administration Code of Federal Regulations. 21CFR11.1, Electronic Records, Electronic Signatures 2013, (Revised as of April 1, 2013).
22. Nielsen S., Hillhouse M., Thomas C., Hasson A., Ling W. A comparison of buprenorphine taper outcomes between prescription opioid and heroin users. Journal of Addiction Medicine 2013, 7(1):33-38.
23. O'Connor P.G. Methods of detoxification and their role in treating patients with opioid dependence. JAMA 2005, 294(8):961-963.
24. Pantalon M.V., Fiellin D.A., Schottenfeld R.S., Gordon L.T., O'Connor P.G. Manual for enhanced medical management of opioid dependence with buprenorphine 1999.
25. Potter J.S., Marino E.N., Hillhouse M.P., Nielsen S., Wiest K., Canamar C.P., et al. Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: Findings from Starting Treatment with Agonist Replacement Therapies (START). Journal of Studies on Alcohol and Drugs 2013, 74:605-613.
26. Potter J.S., Prather K., Kropp F., Byrne M., Sullivan C.R., Mohamedi N., et al. A method to diagnose opioid dependence resulting from heroin versus prescription opioids using the Composite International Diagnostic Interview. Contemporary Clinical Trials 2010, 31(2):185-188.
27. Satre D.D., Chi F.W., Mertens J.R., Weisner C.M. Effects of age and life transitions on alcohol and drug treatment outcome over nine years. Journal of Studies on Alcohol and Drugs 2012, 73(3):459-468.
28. Schutte K.K., Nichols K.A., Brennan P.L., Moos R.H. A ten-year follow-up of older former problem drinkers: risk of relapse and implications of successfully sustained remission. Journal of Studies on Alcohol 2003, 64(3):367-374.
29. SPSS Statistics for Windows Version 20.0 2011, IBM Corp, Armonk, NY.
30. Substance Abuse and Mental Health Services Administration Results from the 2011 National Survey on Drug Use and Health: Summary of National Findings 2012, Substance Abuse and Mental Health Services Administration, Rockville, MD.
31. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality Treatment Episode Data Set (TEDS): 2001-2011. National Admissions to Substance Abuse Treatment Services 2013, Substance Abuse and Mental Health Services Administration, Rockville, MD.
32. Ware J.E., Sherbourne C.D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care 1992, 30(6):473-483.
33. Weiss R.D., Potter J.S., Copersino M.L., Prather K., Jacobs P., Provost S., et al. Conducting clinical research with prescription opioid dependence: defining the population. The American Journal on Addictions 2010, 19(2):141-146.
34. Weiss R.D., Potter J.S., Fiellin D.A., Byrne M., Connery H.S., Dickinson W., et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Archives of General Psychiatry 2011, 68(12):1238-1246.
35. Weiss R.D., Potter J.S., Provost S.E., Huang Z., Jacobs P., Hasson A., et al. A multi-site, two-phase, Prescription Opioid Addiction Treatment Study (POATS): rationale, design, and methodology. Contemporary Clinical Trials 2010, 31(2):189-199.
36. World Health Organization Composite International Diagnostic Interview - Version 2.1 1997, World Health Organization, Geneva, Switzerland.